Monday 1 July 2024

The Pharma Letter Podcast — Episode 14 — A vaccine for Alzheimer's?

Biotechnology
Simon Wentworth
6 June 2022
episode14-big


More on this story...

Biotechnology
Encouraging early results in Alzheimer's for Prothena
26 July 2021
Biotechnology
Prothena pens $1.2 billion deal with Novo Nordisk
12 July 2021
Biotechnology
Roche and Prothena move forward with PD drug prasinezumab
22 October 2020
Biotechnology
Roche's 10-year Alzheimer's study yields depressingly familiar result
16 June 2022


Related Company News

Alzheimer’s drug Leqembi launched in China
BRIEF—FDA accepts Eisai’s sBLA filing for Leqembi
The Pharma Letter M&A roundup - May 2024
Italian watchdog investigating eye disease drug competition
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze